Madrigal Pharmaceuticals Inc

NASDAQ:MDGL   3:59:54 PM EDT
73.02
-1.53 (-2.05%)
Regulatory, Earnings Announcements

Madrigal Pharmaceuticals Provides Clinical And Business Updates And Reports 2022 Second Quarter Financial Results

Published: 08/04/2022 16:31 GMT
Madrigal Pharmaceuticals Inc (MDGL) - Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results.
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results.
Madrigal Pharmaceuticals Inc - Madrigal Remains on Track to Announce Topline Data From Phase 3 Maestro-nash Biopsy Study in Q4.
Madrigal Pharmaceuticals Inc - As of June 30, 2022, Madrigal Had Cash, Cash Equivalents and Marketable Securities of $211.8 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$4.04

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$3.92

More details on our Analysts Page.